Chemotherapy for Breast Cancer Patients with High Recurrence Scores

The prior TAILORx trial — which involved 9719 eligible patients with ER+/HER2−, node-negative breast cancer — showed that, at 9 years, survival was noninferior with endocrine therapy alone versus chemo-endocrine therapy among 6711 women with an intermediate 21-gene recurrence score (RS) of 11 to 25 (NEJM JW Oncol Hematol Jul 2018 and N Engl J Med 2018; 379:111). However, the effect of chemo-endocrine therapy for women with an RS of ≥26 is unclear.

Now, investigators have conducted a retrospective cohort study of 17,197 patients in the National Cancer Database with HR+/HER2−, axillary node–negative, T1-2N0, early-stage breast cancer and an RS of ≥26. Of these patients, 74% received chemo-endocrine therapy (including 38% with RS of 26–30 and 6…